HUP1800298A1 - Combination of beta blocker and hydroximic acid derivative with reduced side effects - Google Patents
Combination of beta blocker and hydroximic acid derivative with reduced side effectsInfo
- Publication number
- HUP1800298A1 HUP1800298A1 HU1800298A HUP1800298A HUP1800298A1 HU P1800298 A1 HUP1800298 A1 HU P1800298A1 HU 1800298 A HU1800298 A HU 1800298A HU P1800298 A HUP1800298 A HU P1800298A HU P1800298 A1 HUP1800298 A1 HU P1800298A1
- Authority
- HU
- Hungary
- Prior art keywords
- combination
- side effects
- acid derivative
- reduced side
- beta blocker
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000002876 beta blocker Substances 0.000 title 1
- 229940097320 beta blocking agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1800298A HUP1800298A1 (en) | 2018-08-30 | 2018-08-30 | Combination of beta blocker and hydroximic acid derivative with reduced side effects |
PCT/HU2019/000033 WO2020044067A1 (en) | 2018-08-30 | 2019-10-30 | Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1800298A HUP1800298A1 (en) | 2018-08-30 | 2018-08-30 | Combination of beta blocker and hydroximic acid derivative with reduced side effects |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP1800298A1 true HUP1800298A1 (en) | 2020-05-28 |
Family
ID=89992747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU1800298A HUP1800298A1 (en) | 2018-08-30 | 2018-08-30 | Combination of beta blocker and hydroximic acid derivative with reduced side effects |
Country Status (2)
Country | Link |
---|---|
HU (1) | HUP1800298A1 (en) |
WO (1) | WO2020044067A1 (en) |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4187220A (en) | 1977-08-30 | 1980-02-05 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
US5123121A (en) | 1988-03-07 | 1992-06-23 | Bell Helmets, Inc. | Helmet retention system with adjustable buckle |
HU207988B (en) | 1988-10-20 | 1993-07-28 | Biorex Kutato Fejlesztoe Kft | Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components |
HU9502843D0 (en) | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
HU222994B1 (en) | 1995-11-02 | 2004-01-28 | BIOREX Kutató és Fejlesztő Rt. | Hydroxylamine derivatives and use thereof in the preparation of a pharmaceutical compositions for enhancing of molecular chaperon production of cells |
US6884424B2 (en) | 1995-12-22 | 2005-04-26 | N-Gene Research Laboratories Inc. | Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight |
US6458371B1 (en) | 1995-12-22 | 2002-10-01 | Medgene, Limited | Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin |
HU9701081D0 (en) | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
HUP9701080A3 (en) | 1997-06-23 | 1999-05-28 | Gene Res Lab Inc New York N | Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative |
WO2000007580A2 (en) | 1998-08-03 | 2000-02-17 | N-Gene Kutató Kft. | Pharmaceutical compositions against autoimmune diseases |
HUP9900475D0 (en) | 1999-02-26 | 1999-04-28 | Biorex Kutato Fejlesztoe Kft | O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component |
PT1268407E (en) | 2000-03-20 | 2004-11-30 | N Gene Res Lab Inc | A derivative of propenoxybarboxylic acid, a process for their preparation and pharmaceutical compositions containing the same |
HUP0001583A2 (en) | 2000-04-18 | 2002-11-28 | BIOREX Kutató és Fejlesztő Rt. | A pyridine-1-oxide derivative and process for its transformation into pharmaceutically effective compounds |
MXPA04000324A (en) | 2001-07-17 | 2004-07-23 | N Gene Res Lab Inc | A synergistic pharmaceutical combination for the prevention or treatment of diabetes. |
HUP0303584A3 (en) | 2003-10-30 | 2009-12-28 | Cytrx Corp | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
HUP0401176A2 (en) | 2004-06-14 | 2007-09-28 | N Gene Res Lab Inc | Pharmaceutical composition having prpkinetic effect |
HUP0401177A2 (en) | 2004-06-14 | 2007-09-28 | N Gene Res Lab Inc | Pharmaceutical composition for increasing the mitochondrial genesis |
HUP0500145A2 (en) | 2005-01-28 | 2006-11-28 | Gene Res Lab N | Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases |
US20080108602A1 (en) | 2006-11-02 | 2008-05-08 | N-Gene Research Laboratories, Inc. | Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication |
US7763601B2 (en) | 2006-11-02 | 2010-07-27 | N-Gene Research Laboratories, Inc. | Prevention and treatment of obesity |
JP2010511622A (en) | 2006-12-01 | 2010-04-15 | シトルックス コーポレイション | Seizure recovery |
TW200901958A (en) | 2007-05-04 | 2009-01-16 | Cytrx Corp | Diabetic wound healing |
US20090281143A1 (en) | 2007-12-10 | 2009-11-12 | N-Gene Research Laboratories, Inc. | Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity |
CA3004867C (en) | 2008-06-26 | 2020-09-15 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
HUP1100445A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
HUP1100444A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
HUP1100534A2 (en) | 2011-09-26 | 2013-04-29 | Balazs Dr Hazay | Pharmaceutical composition for the treatment of muscle atrophy |
HUP1100535A2 (en) | 2011-09-26 | 2013-04-29 | Bracelia Invest Ltd | Pharmaceutical composition for enhancement of stem cell treatment |
PT2968227T (en) * | 2013-03-14 | 2019-05-30 | Univ Berlin Charite | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis |
-
2018
- 2018-08-30 HU HU1800298A patent/HUP1800298A1/en unknown
-
2019
- 2019-10-30 WO PCT/HU2019/000033 patent/WO2020044067A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2020044067A1 (en) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201908154B (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
IL276409A (en) | Methods and compositions for macrophage polarization | |
IL279632A (en) | Compounds and methods for reducing lrrk2 expression | |
IL283042A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
PL3319439T3 (en) | Herbicidal composition comprising cinmethylin and napropamide | |
EP3334484A4 (en) | Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders | |
IL286421A (en) | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | |
IL288024A (en) | Methods and compositions for preventing type | |
EP3638277A4 (en) | Compositions and methods for beta secretase inhibition | |
EP4026831A4 (en) | Piperic acid derivative and application thereof | |
EP3972616A4 (en) | Composition and method for inhibiting amyloid beta accumulation and/or aggregation | |
SG11202010884TA (en) | Dienal compound and flavor composition | |
HUE056154T2 (en) | Pectin compositions for preventing and treating inflammatory diseases | |
GB202007831D0 (en) | Curtain pull | |
HUP1800298A1 (en) | Combination of beta blocker and hydroximic acid derivative with reduced side effects | |
EP3575104A4 (en) | Correction tape capable of self-locking after pushing out guide | |
IL277312A (en) | Beta glucan and cd40 agonist combination immunotherapy | |
EP3904335A4 (en) | Acetylsalicylic acid derivative and application thereof | |
EP3829397A4 (en) | Improved furniture components and assemblies | |
EP3766887A4 (en) | Aniline derivative and use thereof | |
EP3383155A4 (en) | Tape curving attachment and feeder | |
EP3761971A4 (en) | Compositions and methods for inhibiting inflammation | |
GB2594831B (en) | Rheometer systems and related methods | |
AU201810756S (en) | Fittings for curtains and blinds | |
IL281835A (en) | Anti-malaria compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FH91 | Appointment of a representative | ||
FD9A | Lapse of provisional protection due to non-payment of fees |